Streetbeat News

SXTP

60 Degrees Pharmaceuticals, Inc.

https://60degreespharma.com

Industry

Biotechnology

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

Open

0.95

Mkt cap

2.1M

Volume

32K

High

0.95

P/E Ratio

-0.09

52-wk high

18.36

Low

0.86

Div yield

N/A

52-wk low

0.70

60 Degrees Pharmaceuticals Inc. (SXTP) reported a Q3 loss of $0.93 per share, missing the Zacks Consensus Estimate of a $0.60 loss. This is an improvement from the $3.60 loss per share a year ago.

Portfolio Pulse from

November 14, 2024 | 9:45 pm

60 Degrees Pharmaceuticals (SXTP) reported a 164% revenue growth in its third quarter 2024 earnings, along with clinical progress on ARAKODA® for infectious diseases and babesiosis.

Portfolio Pulse from

November 14, 2024 | 7:45 pm

60 Degrees Pharmaceuticals shares rise as the company begins a nine-month promotional pilot for ARAKODA.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 1:11 pm

60 Degrees Pharmaceuticals has launched a nine-month promotional pilot to increase awareness and utilization of ARAKODA, an antimalarial drug, in the U.S. The initiative includes digital outreach and a co-pay program to assist with costs.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 1:09 pm

HC Wainwright & Co. analyst Edward White has reiterated a Neutral rating on 60 Degrees (NASDAQ:SXTP).

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 5:45 pm

Insider buying activity has been observed in three penny stocks: 60 Degrees Pharmaceuticals, Envoy Medical, and Hyliion Holdings. This insider activity may indicate confidence in the companies' prospects. Notably, Hyliion Holdings secured a $15 million contract with the Office of Naval Research.

Portfolio Pulse from Avi Kapoor

September 12, 2024 | 11:19 am

60 Degrees Pharmaceuticals announced a $4M private placement for the sale of shares and warrants, with proceeds intended for working capital, operations, and R&D.

Portfolio Pulse from Benzinga Newsdesk

September 04, 2024 | 12:03 pm

60 Degrees Pharmaceuticals has regained compliance with Nasdaq's minimum bid price requirement as of August 26, 2024, ensuring its continued listing on the Nasdaq Capital Market.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 7:02 pm

60 Degrees Pharmaceuticals shares are trading higher following the company's announcement of a year-over-year increase in Q2 financial results.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 2:15 pm

HC Wainwright & Co. analyst Edward White has reiterated a Neutral rating on 60 Degrees (NASDAQ:SXTP).

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 11:41 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.